Clinical Scorecard: Virtual Staining in the Tumor Microenvironment

At a Glance

Key Highlights

• AI models achieve per-cell AUCs of 0.90 to 0.93 and Pearson correlations exceeding 0.70.
• Virtual staining preserves spatial context of biomarker expression.
• Potential to reduce costs and turnaround time while expanding access to tumor profiling.

Guideline-Based Recommendations

Diagnosis

• Utilize virtual biomarker staining for tissue characterization in NSCLC.

Management

• Incorporate virtual staining in translational research and clinical trials.

Monitoring & Follow-up

• Assess per-cell biomarker expression levels for ongoing patient evaluation.

Risks

• Technical variability in virtual staining may affect reproducibility.

Patient & Prescribing Data

Patients diagnosed with NSCLC requiring tumor microenvironment analysis.

Virtual staining can facilitate biomarker discovery and precision oncology workflows.

Clinical Best Practices

• Leverage virtual biomarker models to enhance tissue analysis efficiency.
• Use archived H&E material for broader access to tumor profiling.

References

• USCAP 2026 Presentation